FTD makes up about at least 5 to 10 % of dementia instances.

Research has shown that breast cancer patients have an elevated level of progranulin in comparison with healthy individuals. We are delighted our clinical research with breast cancer patients and development of progranulin antibodies and assays also will help FTD patients.’.. A&G, Mayo Medical sign license agreement for new progranulin blood check for FTD Mayo Clinic today announced that Mayo Medical Laboratories has signed an agreement with A&G Pharmaceutical, Inc. And will get a nonexclusive license to specific patent rights and proprietary antibody reagents for the recognition and measurement of progranulin in blood. This agreement will let Mayo Clinic offer the first commercial blood check to predict progranulin mutation position in patients suspected to possess frontotemporal dementia .The proposed new plan encourages veterinary pharmacology education through professional pharmacy curricula and continuing education, and reminds pharmacists to verify orders with prescribing veterinarians if there are queries. The plan reminds veterinarians to help make the prescriptions clear also, and consistent with all state rules to avoid medication errors. More information upon this policy and all others approved at the AVMA Table of Director’s springtime meeting is on the AVMA website.

Adeona to build up and commercialize DNA-based therapeutic for PAH using Intrexon technology Adeona Pharmaceuticals, Inc.